Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: A Multicenter, Evaluator-Blind, Prospective, Randomized Study

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 11, 2003, Pages 3442-3447

  Zanetti, G ^a   Bally, F ^a   Greub, G ^a   Garbino, J ^b   Kinge, T ^b   Lew, D ^b   Romand, J A ^b   Bille, J ^a   Aymon, D ^a   Stratchounski, L ^c   Krawczyk, L ^d   Rubinstein, E ^e   Schaller, M D ^a   Chiolero, R ^a   Glauser, M P ^a   Cometta, A ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hôpital Universitaire HUG   (Switzerland)

^c SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^d Intensive Care Unit   (Poland)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFEPIME; CILASTATIN PLUS IMIPENEM;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM DETECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERADICATION THERAPY; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AGED; APACHE; CEPHALOSPORINS; CILASTATIN; CROSS INFECTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMIPENEM; INTENSIVE CARE; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; RESPIRATION, ARTIFICIAL; THIENAMYCINS;

EID: 10744230588     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.11.3442-3447.2003     Document Type: Article

References (30)

1. Alvarez-Lerma, F., et al. 1996. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 22:387-394.
2. Barckow, D., and C. D. Schwigon. 1993. Cefepime versus cefotaxime in the treatment of lower respiratory tract infections. J. Antimicrob. Chemother. 32(Suppl. B):187-193.
3. Beam, T. R., D. N. Gilbert, C. M. Kunin, et al. 1992. General guidelines for the clinical evaluation of anti-infective drug products. Clin. Infect. Dis. 15(Suppl. 1):S5-S32.
4. Beam, T. R., D. N. Gilbert, and C. M. Kunin. 1993. European guidelines for anti-infective drug products. Introduction. Clin. Infect. Dis. 17:787-788.
5. Chastre, J., J. Y. Fagon, and J. Y. Fagon. 2002. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165:867-903.
6. Chow, A. W., C. B. Hall, J. O. Klein, R. B. Kammer, R. D. Meyer, J. S. Remington, et al. 1992. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Clin. Infect. Dis. 15(Suppl. 1):S62-S88.
7. Cometta, A., J. D. Baumgartner, D. Lew, W. Zimmerli, D. Pittet, P. Chopart, U. Schaad, C. Herter, P. Eggimann, and O. Huber. 1994. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. 38:1309-1313.
8. Cook, D. J., S. D. Walter, R. J. Cook, L. E. Griffith, G. H. Guyatt, D. Leasa, R. Z. Jaeschke, and C. Brun-Buisson. 1998. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann. Intern. Med. 129:433-440.
9. Croce, M. A., T. C. Fabian, R. M. Stewart, F. E. Pritchard, G. Minard, L. Trenthem, and K. A. Kudsk. 1993. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J. Trauma-Injury Infect. Crit. Care 35:303-309.
10. Edelstein, H., V. Chirurgi, S. Oster, R. Karp, K. Cassano, S. Aiken, and R. McCabe. 1991. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J. Antimicrob. Chemother. 28:569-575.
11. Fagon, J. Y., J. Chastre, A. J. Hance, P. Montravers, A. Novara, and C. Gibert. 1993. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay. Am. J. Med. 94:281-288.
12. Fagon, J. Y., J. Chastre, A. Vuagnat, J. L. Trouillet, A. Novara, and C. Gibert. 1996. Nosocomial pneumonia and mortality among patients in intensive care units. JAMA 275:866-869.
13. Fink, M. P., D. R. Snydman, M. S. Niederman, K. V. Leeper, Jr., Johnson, R. H., S. O. Heard, R. G. Wunderink, J. W. Caldwell, J. J. Schentag, G. A. Siami, and The Severe Pneumonia Study Group. 1994. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob. Agents Chemother. 38:547-557.
14. Hartenauer, U., L. S. Weilemann, K. F. Bodmann, W. W. Ritzerfeld, S. Asmus, and E. M. Koch. 1990. Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias. J. Hosp. Infect. 15(Suppl. A):61-64.
15. Jaccard, C., N. Troillet, S. Harbarth, G. Zanetti, D. Aymon, R. Schneider, R. Chiolero, B. Ricou, J. Romand, O. Huber, P. Ambrosetti, G. Praz, D. Lew, J. Bille, M. P. Glauser, and A. Cometta. 1998. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob. Agents Chemother. 42:2966-2972.
16. Jones, R. N., and S. A. Marshall. 1994. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. Diagn. Microbiol. Infect. Dis. 19:33-38.
17. Kollef, M. H. 1999. Antimicrobial therapy of ventilator-associated pneumonia: how to select an appropriate drug regimen. Chest 115:8-11.
18. Kollef, M. H., and S. Ward. 1998. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 113:412-420.
19. Leophonte, P., A. Bertrand, G. Nouvet, J. F. Muir, F. Lucht, P. Delaval, A. Depierre, F. Hughes, M. Ulmer, and J. J. Gres. 1993. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 32(Suppl. B):165-173.
20. Leu, H. S., D. L. Kaiser, M. Morí, R. F. Woolson, and R. P. Wenzel. 1989. Hospital-acquired pneumonia. Attributable mortality and morbidity. Am. J. Epidemiol. 129:1258-1267.
21. Liu, Y. C., W. K. Huang, and D. L. Cheng. 1994. Antibacterial activity of cefepime in vitro. Chemotherapy 40:384-390.
22. Luna, C. M., P. Vujacich, M. S. Niederman, C. Vay, C. Gherardi, J. Matera, and E. C. Jolly. 1997. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111:676-685.
23. National Committee for Clinical Laboratory Standards. 1987. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards Villanova, Pa.
24. Pugin, J., R. Auckenthaler, N. Mili, J. P. Janssens, P. D. Lew, and P. M. Suter. 1991. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am. Rev. Respir. Dis. 143:1121-1129.
25. Rello, J., M. Gallego, D. Mariscal, R. Sonora, and J. Valles. 1997. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:196-200.
26. Sanders, C. C. 1993. Cefepime: the next generation? Clin. Infect. Dis. 17:369-379.
27. Timsit, J. F., S. Chevret, J. Valcke, B. Misset, B. Renaud, F. W. Goldstein, P. Vaury, and J. Carlet. 1996. Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools. Am. J. Respir. Crit. Care Med. 154:116-123.
28. Torres, A., R. Aznar, J. M. Gatell, P. Jimenez, J. Gonzalez, A. Ferrer, R. Celis, and R. Rodriguez-Roisin. 1990. Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. Am. Rev. Respir. Dis. 142:523-528.
29. Troillet, N., M. H. Samore, and Y. Carmeli. 1997. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin. Infect. Dis. 25:1094-1098.
30. Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M. H. Nicolas-Chanoin, M. Wolff, R. C. Spencer, M. Hemmer, et al. 1995. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 274:639-644.